HCR Monthly Blog

The US Rx Tax Exodus: Is Something “Probably Wrong” with Our System?

July 9th, 2014 Tom Norton

As I read the latest reports of yet another big US Rx firm, this time AbbVie, trying to pull off a “tax inversion” takeover of the Irish-based Shire, I couldn’t help but wonder, what the heck is going on here? Right now, it feels like most major US corporations, especially pharmas, are literally running away read more

 

What Does ‘Off Label’ Mean in 2014?

June 12th, 2014 Tom Norton

Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s not the approved read more

 

Obamacare’s “Unacceptable” Rx Copays

May 28th, 2014 Tom Norton

We are now approaching the six month point in the implementation of the new Obamacare program. It’s senseless to go into the good, bad and ugly of this new program. While much of the concept continues to be thrashed about in the political arena, in terms of actual medical results the truth of what Obamacare read more

 

The United Kingdom: Rx for America’s Pharma Tax Blues?

April 29th, 2014 Tom Norton

The dizzying flurry of press releases from both Pfizer Inc. and AstraZeneca over a possible PFE acquisition of AZN have Rx experts on both sides of the Atlantic buzzing… From the US side, the most frequent thing that I have heard over the last 48 hours is, “You have got to be kidding! Pfizer’s last read more